Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
PDUFA
Pharma
Regeneron's Evkeeza gets priority look for use in kids with HoFH
Regeneron has gained priority review status from the FDA for Evkeeza's use in children ages 5 to 11 with the ultra-rare genetic disorder HoFH.
Kevin Dunleavy
Nov 30, 2022 11:19am
ImmunoGen gains FDA nod for advanced ovarian cancer drug Elahere
Nov 15, 2022 11:03am
FDA accepts AZ's application for tremelimumab in liver cancer
Apr 25, 2022 9:29am
FDA missing PDUFA targets as COVID slows plant inspections
Oct 19, 2021 9:35am
FDA recalls inspectors as government shutdown drags on
Jan 16, 2019 10:42am
FDA holds off on job cuts, assures workers fees to be authorized
Jul 26, 2017 11:49am
